Securing a new pipeline and accelerating the development of new microbiome drugs

On March 27, 2023 CJ Bioscience reported it has signed a contract to acquire a promising new drug candidate and platform technology owned by 4D Pharma, a microbiome company based in the UK and Ireland (Press release, CJ Bioscience, MAR 27, 2023, View Source [SID1234632171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A total of nine new drug candidates are introduced, targeting solid cancers, digestive diseases, brain diseases, and immune diseases. In addition, it plans to acquire all related intellectual property rights such as patents, including two cases of 4D Pharma’s diagnostic and new drug candidate discovery technology platforms, and the contract amount has not been disclosed in accordance with the agreement between the two companies.

In addition, greater synergy is expected when the new drug candidate secured through this contract is combined with the Ez-Mx Platform, which is based on CJ Bioscience’s bioinformatics technology. In addition, 4D Pharma’s new drug development technology and know-how accumulated over 10 years are added to accelerate the development of new microbiome drugs.

CJ Bioscience plans to reflect it in its R&D strategy after analyzing detailed data of each pipeline. The company plans to prioritize clinical trials focusing on candidates with high potential for success, including CJRB-101, an immune anti-cancer treatment that received clinical approval from the US Food and Drug Administration (FDA) in January. The microbiome drug market is expected to grow explosively to $1 billion by 2030, and CJ Bioscience plans to conduct clinical research with the goal of leading the market.

An official from CJ Bioscience said, "The introduction of the new pipeline has given us the world’s best microbiome-based new drug development competitiveness. I will do it," he said.